Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, ...

Learn more about whether Ultragenyx Pharmaceutical Inc. or Vericel Corporation is a better investment based on AAII's A+ ...

The phase 2 REST trial by Frida Bugge Askeland and colleagues, reported in The Lancet Haematology, provides insight into ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...

Antibody Therapy MarketThe global antibody therapy market is on a strong growth trajectory, projected to expand at a CAGR of ...

Long-term treatment with lebrikizumab may be beneficial for patients with atopic dermatitis that were not initially ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $945.56, a high ...

The next phase of pre-exposure prophylaxis against SARS-CoV-2 currently rests on the shoulders of a single monoclonal ...

Despite its vital role in "kick-starting" the immune response, IgD is arguably the least understood antibody, with little known about how it might participate in other parts of the immune system. A ...

A single dose of the COVID-19 monoclonal antibody therapy developing Regeneron reduced the risk of contracting the virus by around 82% for up to eight months, according to new trial data.